Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025)
Scynexis' (SCYX) quarterly Non-Current Deffered Revenue came in at $807000.0 in Q3 2025, down 37.92% on a YoY basis from $1.3 million in Q3 2024, and up 56.7% quarter-over-quarter from $515000.0 in Q2 2025.
Analysis
Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025) Analysis & Trends
Scynexis (SCYX) has reported Non-Current Deffered Revenue for 9 consecutive years, with $807000.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 37.92% year-over-year to $807000.0; the trailing twelve-month figure through Sep 2025 stood at $807000.0 (down 37.92% YoY), and the FY2024 full-year result was $1.3 million, down 52.33% from the prior year.
- Non-Current Deffered Revenue advanced to $807000.0 in Q3 2025 per SCYX's latest filing, from $515000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.7 million in Q4 2023 and bottomed at $515000.0 in Q2 2025.
- Historically, Non-Current Deffered Revenue has averaged $1.5 million across 3 years, with a median of $1.3 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue jumped 59.39% in 2024, then tumbled 71.66% in 2025.
- Over 3 years, Non-Current Deffered Revenue stood at $2.7 million in 2023, then tumbled by 52.33% to $1.3 million in 2024, then sank by 37.92% to $807000.0 in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $807000.0, $515000.0, and $1.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 807,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2018 | 57,000.00 |
| Dec 31, 2017 | 121,000.00 |
| Sep 30, 2017 | 185,000.00 |
| Jun 30, 2017 | 249,000.00 |
| Mar 31, 2017 | 314,000.00 |
| Dec 31, 2016 | 378,000.00 |
| Sep 30, 2016 | 442,000.00 |
| Jun 30, 2016 | 507,000.00 |
| Mar 31, 2016 | 571,000.00 |
| Dec 31, 2015 | 635,000.00 |